{
  "schema_version": "1.0",
  "type": "article",
  "title": "瘦瘦針的雙藥賭注",
  "url": "https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.md",
  "lang": "zh-Hant",
  "date": "2026-10-14",
  "publish_at": "2026-10-14T08:00:00+08:00",
  "updated_at": "2026-10-14",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "EloraTZP",
    "eloralintide",
    "tirzepatide",
    "肥胖",
    "臨床試驗"
  ],
  "summary": "禮來在第二期試驗把eloralintide加入tirzepatide，換到額外減重潛力，也遇到較高的因不良事件停藥比例。第三期的加量節奏與共製劑，能否讓這段藥效成為病人願意持續接受的產品升級，仍待驗證。",
  "key_points": [],
  "facts": [],
  "sections": [
    "01｜新搭檔先得勝過自家的現成選項",
    "02｜另一欄數字，讓升級多了一筆代價",
    "03｜多一條作用路徑，也多一道產品考題",
    "04｜做成共製劑，還要跨過耐受這一關",
    "結語｜值得往前押，下一關看取捨",
    "參考資料"
  ],
  "references": [
    {
      "title": "Lilly",
      "source": "EloraTZP第二期結果、試驗設計、效力估計註腳、不良事件與第三期開發計畫，2026年9月30日。",
      "date": "",
      "url": "https://lilly.gcs-web.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide"
    },
    {
      "title": "Aronne等",
      "source": "SURMOUNT-4，JAMA 2024；331:38–48。停藥與持續治療的背景研究，並非EloraTZP試驗。",
      "date": "",
      "url": "https://jamanetwork.com/journals/jama/fullarticle/2812936"
    }
  ],
  "images": [
    {
      "alt": "圖1｜同一第二期試驗、第48週的平均體重減幅；對象有第二型糖尿病及肥胖或過重。9＋15毫克是兩藥各自的劑量，本次分開注射，圖中的筆形僅為示意。23.3%與14.8%是持續治療假設下的估計，差距為8.5個百分點。",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/figure-01.png"
    },
    {
      "alt": "圖2｜23.3%是在持續接受研究治療的假設下估計。圖中虛線是統計假設的示意，不是觀察到的患者軌跡；效力估計也不等於只計算完成者。",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/figure-02.png"
    },
    {
      "alt": "圖3｜eloralintide作用於胰澱素受體，tirzepatide作用於GIP與GLP-1受體。圖為作用路徑示意，並非完整的器官訊號圖；兩分子共同使用的價值，仍由人體試驗判斷。",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/figure-03.png"
    },
    {
      "alt": "圖4｜加量、耐受與持續追蹤需要一起設計。優化方案尚待驗證；圖中的階梯不是實際劑量或調整時程，也不是個人用藥指引。",
      "url": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/figure-04.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/eloratzp-weight-loss-tolerability-persistence/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-14）。瘦瘦針的雙藥賭注。https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {}
}